Apnimed (APMD) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apnimed is the larger company by market cap ($669.8 million vs $616.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | JANX |
|---|---|---|
| Share price | $16.09 | $10.08 |
| Market cap | $669.84M | $616.73M |
| 1-day change | -6.70% | -2.04% |
| YTD return | — | -26.96% |
| 1-year return | — | -65.00% |
| 5-year return | — | -42.92% |
| P/E ratio (TTM) | 1.21 | — |
| EPS (TTM) | $13.34 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.00M |
| Revenue growth (YoY) | — | -5.55% |
| Net income (latest FY) | — | $-113.63M |
| Operating margin | — | -1576.67% |
| Net margin | — | -1136.25% |
| 52-week high | $35.29 | $35.34 |
| 52-week low | $13.88 | $10.05 |
| Distance from 52-week high | -54.41% | -71.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +210.75% | +228.77% |
| Average volume | 458.58K | 961.56K |
| Shares outstanding | 41.63M | 61.18M |
| Employees | 112 | 114 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
APMD vs JANX FAQ
Which is bigger, Apnimed or Janux Therapeutics?
Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $616.73M for Janux Therapeutics (JANX).
Are Apnimed and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.